Other languages Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Real-time Estimate Cboe BZX Other stock markets 11:06:01 2024-04-29 EDT			5-day change	1st Jan Change
21.88 ^USD	+4.86%		+2.65%	-39.86%

03-04	Prothena Names David Ford as Chief People Officer	MT
03-04	Prothena Appoints David Ford to Newly Created Chief People Officer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prothena Appoints David Ford to Newly Created Chief People Officer	03-04
Prothena Corporation plc Announces Board Changes	02-21
Sector Update: Health Care Stocks Gain Pre-Bell Friday	02-16
Prothena Posts Q4 Net Loss as Revenue Slumps	02-15
Prothena Corporation plc Provides Earnings Guidance for the Year 2024	02-15
Prothena Corporation plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15
Researchers return to Alzheimer's vaccines, buoyed by recent drug success	11-20
Prothena Corporation plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02
Prothena Corp Public Ltd Insider Sold Shares Worth $205,191, According to a Recent SEC Filing	23-10-26
Prothena preparing for a potential sale - Bloomberg News	23-10-16
Prothena Exploring Sale of Company; Shares Rise	23-10-16
Prothena Reportedly Prepares for Potential Sale	23-10-16
Prothena Corp Public Ltd Insider Sold Shares Worth $186,985, According to a Recent SEC Filing	23-10-12
Prothena Corp Public Ltd Insider Sold Shares Worth $233,084, According to a Recent SEC Filing	23-10-05
Prothena Corp Public Ltd Insider Sold Shares Worth $261,807, According to a Recent SEC Filing	23-09-19
Prothena Corporation plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Prothena Corporation plc Presents New Research in the Treatment of Alzheimer's Disease At Alzheimer's Association International ConferenceÂ®? 2023	23-07-17
Prothena Corporation plc Announces Bristol Myers Squibb Opt-In for Worldwide Rights of Prx005, A Novel Anti-Mtbr-Tau Antibody	23-07-10
Prothena Says Phase 3 Trial Data Showed Survival Benefit in People With AL Amyloidosis Treated With Birtamimab	23-06-27
Prothena C Corporation plc Announces Phase VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV Al Amyloidosis Treated with Birtamimab	23-06-27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Other languages

Filters